Need to keep on prime of the science and politics driving biotech immediately? Join to get our biotech publication in your inbox.
Good morning. Right this moment we have a look at how RFK Jr. is cementing his energy and the way his division’s insurance policies are main some scientists to depart the U.S.
The necessity-to-know this morning
- Cytokinetics mentioned Chinese language regulators authorized Myqorzo (previously aficamten) for the remedy of a severe coronary heart situation often known as obstructive hypertrophic cardiomyopathy. An approval determination from the FDA is anticipated earlier than the top of the yr. Sanofi has rights to promote Myqorzo in China.
- DBV Applied sciences mentioned its Viaskin peanut patch lowered allergic reactions in kids, attaining the first purpose of a Part 3 scientific trial. The corporate plans to submit for FDA approval subsequent yr.
Some scientists are leaving the U.S. as Trump insurance policies destabilize analysis prospects
The volatility of federal analysis funding underneath the Trump administration has stoked fears of a U.S. mind drain. Whereas it’s too early to know what number of scientist have left or will go away the nation this yr, there are some indicators that extra researchers are wanting overseas.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.